Showing items related by title, author, creator and subject.

• Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. 

  Huh, WK; Joura, EA; Giuliano, AR; Iversen, O-E; de Andrade, RP; Ault, KA; Bartholomew, D; Cestero, RM; Fedrizzi, EN; Hirschberg, AL (2017-11-11)

  BACKGROUND: Primary analyses of a study in young women aged 16-26 years showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine against infections and disease ...

• New strategies for human papillomavirus-based cervical screening. 

  Lorincz, A; Castanon, A; Wey Lim, AW; Sasieni, P (2013-09)

  Human papillomavirus testing has been shown to be far more sensitive and robust in detecting cervical intraepithelial neoplasia 2 and above (and cervical intraepithelial neoplasia 3 and above) for cervical screening than ...

• The Role of Human Papillomaviruses and Polyomaviruses in BRAF-Inhibitor Induced Cutaneous Squamous Cell Carcinoma and Benign Squamoproliferative Lesions. 

  Purdie, KJ; Proby, CM; Rizvi, H; Griffin, H; Doorbar, J; Sommerlad, M; Feltkamp, MC; der Meijden, EV; Inman, GJ; South, AP (2018)

  Background: Human papillomavirus (HPV) has long been proposed as a cofactor in the pathogenesis of cutaneous squamous cell carcinoma (cSCC). More recently, the striking clinico-pathological features of cSCCs that complicate ...